CALQUENCE PRESCRIBING INFORMATION
Table 1: Recommended Dose Modifications for Use with CYP3A Inhibitors or Inducers CYP3A Co-administered Drug Recommended CALQUENCE use Inhibition Strong CYP3A inhibitor Avoid concomitant use. If these inhibitors will be used short-term (such as anti-infectives for up to seven days), interrupt CALQUENCE. Moderate CYP3A inhibitor 100 mg once daily.
Download CALQUENCE PRESCRIBING INFORMATION
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Documents from same domain
Imfinzi Full Prescribing Information
den8dhaj6zs0e.cloudfront.netlung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. (1.1) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). (1.2)
Lynparza Prescribing Information
den8dhaj6zs0e.cloudfront.net5.4 Venous Thromboembolic Events 6 ADVERSE REACTIONS 6.1 Clinical Trial Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 7.1 Use with Anticancer Agents 7.2 Effect of Other Drugs on Lynparza 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.3 Females and Males of Reproductive Potential 8.5 Geriatric Use 8.6 Renal Impairment
Information, Prescribing, Pregnancy, Prescribing information, Thromboembolic
BREZTRI Full Prescribing Information
den8dhaj6zs0e.cloudfront.netIf the inhaler has not been used for more than 7 days, is dropped, or after weekly . cleaning, prime the inhaler again by releasing 2 sprays into the air away from the face, shaking well before each spray. 2.3 Dose counter. BREZTRI AEROSPHERE canister has an attached dose indicator, which indicates . how many inhalations remain.
Information, Prescribing, Dose, Prescribing information, Inhaler
SYMBICORT Medication Guide
den8dhaj6zs0e.cloudfront.netSYMBICORT comes in 2 strengths. Your healthcare provider has prescribed the strength that is best for you. Note the differences between SYMBICORT and your other inhaled medications, including the differences in prescribed use and physical appearance.
SYMBICORT Prescribing Information
den8dhaj6zs0e.cloudfront.net5.18 Hypokalemia and Hyperglycemia. 6 ADVERSE REACTIONS. 6.1 Clinical Trials Experience in Asthma 6.2 Clinical Trials Experience in Chronic Obstructive Pulmonary Disease. 6.3 Postmarketing Experience. 7 DRUG INTERACTIONS. Antidepressants 7.3 Beta-Adrenergic Receptor Blocking Agents 7.4 Diuretics. 8 USE IN SPECIFIC POPULATIONS. 8.1 Pregnancy …
US-56427 ---------------------------- DOSAGE AND ...
den8dhaj6zs0e.cloudfront.netnot start BRILINTA in patients undergoing urgent coronary artery bypass graft surgery (CABG). (5.1, 6.1) • If: possible, manage bleeding without discontinuing ----- BRILINTA. Stopping BRILINTA increases the risk of subsequent cardiovascular events. (5.4) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS IN PATIENTS WITH ACS ...
Farxiga Prescribing Information
den8dhaj6zs0e.cloudfront.netpatients with polycystic kidney disease or patients requiring or with a recent . history of immunosuppressive therapy for the treatment of kidney disease. FARXIGA is not expected to be effective in these populations. (1)----- DOSAGE AND ADMINISTRATION ----- • Assess volume status and correct volume depletion before initiating. ...
Information, Disease, Prescribing, Kidney, Prescribing information, Kidney disease, Polycystic, Polycystic kidney disease
FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE ...
den8dhaj6zs0e.cloudfront.netHealthcare Providers for detail on preparation and administration. (2) ... registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs in the therapeutic class to which EVUSHELD belongs (i.e., anti-infectives).
CRESTOR PRESCRIBING INFORMATION
den8dhaj6zs0e.cloudfront.netreduce elevated total-C, LDL-C, ApoB, nonHDL-C, and TG levels and to increase HDL-C (1.1) ... Monitor INR frequently until stable upon initiation or alteration of CRESTOR therapy. (5.4, 7.6) • Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (≥1 g/day)
Saphnelo full Prescribing Information
den8dhaj6zs0e.cloudfront.netwith severe active lupus nephritis or severe active central nervous system lupus. Use . of SAPHNELO is not recommended in these situations. (1)----- DOSAGE AND ADMINISTRATION -----The recommended dosage is 300 mg as an intravenous infusion over a 30-minute . …
Related documents
Dose Conversion Chart for PPIs for IV Administration
www.clevelandclinicmeded.comthe Cleveland Clinic Hospitals have made a change in the automatic therapeutic interchange for the proton pump inhibitors (PPIs). As of January 3, 2006, the PPI on the Cleveland Clinic Formulary for adult patients who do not require a suspension is esomeprazole (Nexium®). All new medication orders for PPIs (e.g., lansoprazole, omeprazole ...
Proton Pump Inhibitors: Use in Pediatric Patients
www.cms.gov2 Proton Pump Inhibitors: Use in Pediatric Patients. FDA-Approved Indications for Proton Pump Inhibitors in Pediatric Patients. Medications in the PPI drug therapy class have been proven safe and effective in children and adolescents for . the short-term treatment of GERD and EE. However, PPIs are often used to treat conditions that have not been
Patients, Pumps, Pediatric, Inhibitors, Use in pediatric patients, Pump inhibitors, Pump inhibitors in pediatric patients
CELLCEPT Prescribing Information - Genentech
www.gene.comproton pump inhibitors, drugs that interfere with enterohepatic recirculation, telmisartan, calcium-free phosphate binders. ... · Pediatric Use: Safety and effectiveness in allogenic heart or liver ... suspension for pediatric kidney transplant patients 3 months and older is 600 mg/m2, ...
Patients, Pumps, Pediatric, Inhibitors, Genentech, Pediatric use, Pump inhibitors
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
www.merck.com8.4 Pediatric Use 8.5 Geriatric Use 8.6 Hepatic Impairment 8.7 Renal Impairment 8.8 Race/Ethnicity 11 DESCRIPTION ... ENTEREG is not recommended for use inthese patients. 6 ADVERSE REACTIONS ... (proton pump inhibitors (PPIs), histamine-2 ...
Information, Patients, Pumps, Pediatric, Prescribing, Prescribing information, Inhibitors, Pediatric use, Pump inhibitors
HIGHLIGHTS OF PRESCRIBING INFORMATION ——— …
www.novo-pi.com• For pediatric patients requiring less than 5 units of TRESIBA ® each day, use a TRESIBA U-100 vial (2.1). • In adults, inject subcutaneously once daily at any time of day (2.2). • In pediatric patients inject subcutaneously once daily at the same time every day (2.2). • Individualize dose based on type of diabetes, metabolic
Information, Patients, Pediatric, Prescribing, Prescribing information, Pediatric patients, In pediatric patients
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.talicia.comTALICIA is contraindicated in patients with known hypersensitivity to the components of TALICIA: amoxicillin [or other β-lactam antibacterial drugs (e.g., penicillins and cephalosporins)], omeprazole (or other benzimidazoles [e.g. proton pump inhibitors (PPIs) and anthelmintics]), rifabutin (or any other rifamycins), or
Perioperative Medication Management - Adult/Pediatric ...
www.uwhealth.orgJul 27, 2020 · 1.2 Proton pump inhibitors: dexlansoprazole, esomeprazole, lansoprazole, omeprazole, omeprazole/sodium bicarbonate, pantoprazole, rabeprazole 1.2.1 Parathyroid surgery 1.2.1.1 Recommend to hold proton pump inhibitors 7 days prior to and day of surgery and post-operatively until directed to resume by surgeon. (UW Health strong